CELL SIGNALING TECHNOLOGY, INC.
Patent Owner
Stats
- 46 US PATENTS IN FORCE
- 10 US APPLICATIONS PENDING
- Mar 20, 2018 most recent publication
Details
- 46 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 676 Total Citation Count
- Nov 13, 2001 Earliest Filing
- 59 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0031,559 METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPYOct 12, 17Feb 01, 18[G01N, C07K]
2018/0009,884 Production of Motif-Specific and Context-Independent Antibodies Using Peptide Libraries as AntigensAug 21, 17Jan 11, 18[C07K]
2015/0184,158 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMASep 11, 14Jul 02, 15[C12N]
2013/0059,305 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMASep 14, 12Mar 07, 13[C12Q, G01N]
2012/0308,555 METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIESMar 09, 12Dec 06, 12[A61K, C40B, C07K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9738711 Production of motif-specific and context-independent antibodies using peptide libraries as antigensDec 17, 14Aug 22, 17[C07K]
9587013 Immunoaffinity isolation of modified peptides from complex mixturesApr 23, 13Mar 07, 17[G01N, C07K, B01D]
9588110 Multi component antibody based detection technologyJul 27, 12Mar 07, 17[C12Q, C12N, G01N, C07K]
9523130 Methods of treating non-small cell lung carcinoma (NSCLC)Aug 02, 16Dec 20, 16[A61K, C12Q, C12N, G01N]
9453845 Mass spectroscopy analysis of mutant polypeptides in biological samplesFeb 01, 11Sep 27, 16[H01J, C12Q, G01N, B01D]
9328349 Translocation and mutant ROS kinase in human non-small cell lung carcinomaSep 11, 14May 03, 16[A61K, C12Q, C12N, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0091,493 METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPYAbandonedDec 10, 15Mar 31, 16[G01N]
2014/0134,640 Gene Defects And Mutant ALK Kinase In Human Solid TumorsAbandonedJul 12, 13May 15, 14[G01N]
2013/0266,965 Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHAAbandonedFeb 28, 13Oct 10, 13[G01N]
2013/0209,452 GENE DEFECTS AND MUTANT ALK KINASE IN HUMAN SOLID TUMORSAbandonedSep 14, 12Aug 15, 13[A61K, C12Q, G01N]
8446160 Probe card maintenance method which adjusts position/posture of probesExpiredFeb 01, 10May 21, 13[G01R]
2013/0071,841 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMAAbandonedOct 01, 12Mar 21, 13[C12Q, G01N]
2013/0059,304 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMAAbandonedSep 14, 12Mar 07, 13[C12Q, G01N]
2012/0244,594 Immunoaffinity isolation of modified peptides from complex mixturesAbandonedJun 28, 07Sep 27, 12[H01J, C12S, C12N, G01N, C07K, B01D]
2012/0149,880 Nucleic Acid Cassette For Producing Recombinant AntibodiesAbandonedAug 20, 10Jun 14, 12[C12P, C12N, C07K]
2012/0101,108 Anaplastic Lymphoma Kinase In Kidney CancerAbandonedAug 05, 11Apr 26, 12[A61K, C12Q, G01N]
2011/0130,547 Reagents For The Detection Of Protein Phosphorylation In EGFR Signaling PathwaysAbandonedOct 04, 10Jun 02, 11[C07K]
2011/0104,820 Tyrosine, Serine, And Threonine Phosphorylation SitesAbandonedOct 12, 10May 05, 11[G01N, C07K]
2011/0105,732 Reagents for the Detection of Protein Phosphorylation in Carcinoma Signaling PathwaysAbandonedJan 06, 11May 05, 11[C07K]
2011/0045,534 Nucleic Acid Cassette For Producing Recombinant AntibodiesAbandonedNov 23, 09Feb 24, 11[C07H, C12P, C12N, C07K]
2011/0045,603 Serine, Threonine, and Tyrosine Phosphorylation SitesAbandonedApr 20, 10Feb 24, 11[G01N, C07K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.